Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK and Bronchodilator Properties of V0162 in Healthy Volunteers and COPD Patients
NCT01348555Phase 2Completed
- Sponsor
- Pierre Fabre Laboratories
- Start
- Apr 2011
- Primary completion
- Jul 2012
- Modality
- Orthosteric Ligands
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of (R)-mequitazine in chronic obstructive pulmonary disease (COPD), sponsored by Pierre Fabre Laboratories. Primary endpoint: Local tolerability of V0162 at 72 hours. Started Apr 2011; status: completed.
02
Drugs
(R)-mequitazine
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT01348555.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01348555.